Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Maxwell O Akanbi, Kimberly Scarsi, Babafemi Taiwo & Robert L Murphy. (2012) Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection. Expert Opinion on Pharmacotherapy 13:1, pages 65-79.
Read now
Read now
Miguel Goicoechea & Brookie Best. (2007) Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?. Expert Opinion on Pharmacotherapy 8:3, pages 371-382.
Read now
Read now
Richard Elion, Calvin Cohen, Edwin deJesus, Robert Redfield, Joseph Gathe, Ricky Hsu, Linda Yau, Lisa Ross, Belinda Ha, Randall Lanier & Trevor Scott. (2006) Once-Daily Abacavir/Lamivudine/Zidovudine plus Tenofovir for the Treatment of HIV-1 Infection in Antiretroviral-NaïveSubjects: A 48-Week Pilot Study. HIV Clinical Trials 7:6, pages 324-333.
Read now
Read now
Claudio M Mastroianni, Gabriella d’Ettorre & Vincenzo Vullo. (2006) Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. Expert Opinion on Pharmacotherapy 7:16, pages 2233-2241.
Read now
Read now
Articles from other publishers (28)
Herman G Sprenger, Wouter FW Bierman, Tjip S van der Werf, Elisabeth H Gisolf & Clemens Richter. (2013) A Systematic Review of a Single-Class Maintenance Strategy with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Hiv/Aids. Antiviral Therapy 19:7, pages 625-636.
Crossref
Crossref
Roland Landman, Sinata Koulla-Shiro, Papa Salif Sow, Maguy Ngolle, Mahamadou-Baila Diallo, Ndèye Fatou Ngom Guèye, Vincent Le Moing, Sabrina Eymard-Duvernay, Aïda Benalycherif, Charlotte Charpentier, Gilles Peytavin, Eric Delaporte & Pierre-Marie Girard. (2014) Evaluation of Four Tenofovir-Containing Regimens as First-Line Treatments in Cameroon and Senegal: The Anrs 12115 Dayana Trial. Antiviral Therapy 19:1, pages 51-59.
Crossref
Crossref
Michael Neely, Richard Rutstein, Gabriela Del Bianco, Gloria Heresi, Theresa Barton, Andrew Wiznia, Ryan Wiegand, Travis Wheeling, Beverly Bohannon & Kenneth Dominguez. (2013) Use of Nucleoside Reverse Transcriptase Inhibitor–only Regimens in HIV-infected Children and Adolescents. Pediatric Infectious Disease Journal 32:9, pages e370-e376.
Crossref
Crossref
Michele W. Tang, Phyllis J. Kanki & Robert W. Shafer. (2012) A Review of the Virological Efficacy of the 4 World Health Organization–Recommended Tenofovir-Containing Regimens for Initial HIV Therapy. Clinical Infectious Diseases 54:6, pages 862-875.
Crossref
Crossref
Douglas Barnas, Dianna Koontz, Holly Bazmi, Christian Bixby, Joseph Jemsek & John W Mellors. (2009) Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir. Antiviral Therapy 15:3, pages 437-441.
Crossref
Crossref
Miguel Goicoechea, Sonia Jain, Lucun Bi, Carol Kemper, Eric S Daar, Catherine Diamond, Belinda Ha, John Flaherty, Shelly Sun, Douglas Richman, Stan Louie & Richard Haubrich. (2010) Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS 24:5, pages 707-716.
Crossref
Crossref
S. Di Giambenedetto, C. Torti, M. Prosperi, N. Manca, G. Lapadula, G. Paraninfo, N. Ladisa, M. Zazzi, M. Trezzi, P. Cicconi, P. Corsi, P. Nasta, R. Cauda & A. De Luca. (2009) Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: Predictors of virological response and drug resistance evolution in a multi-cohort study. Infection 37:5, pages 438-444.
Crossref
Crossref
R. Landman, C. Capitant, D. Descamps, C. Chazallon, G. Peytavin, C. Katlama, G. Pialoux, M. Bentata, F. Brun-Vezinet, J.-P. Aboulker & P. Yeni. (2009) Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. Journal of Antimicrobial Chemotherapy 64:1, pages 118-125.
Crossref
Crossref
Magdalena E. Sobieszczyk, Barbara S. Taylor & Scott M. Hammer. 2009. Clinical Virology. Clinical Virology
167
216
.
M. Perez‐Olmeda, J. Garcia‐Perez, E. Mateos, S. Spijkers, M.C. Ayerbe, A. Carcas & J. Alcami. (2008) In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. Journal of Medical Virology 81:2, pages 211-216.
Crossref
Crossref
Albert ML AndersonJeffrey L Lennox. (2009) Abacavir/lamivudine fixed dose combination in the treatment of patients with HIV infection. HIV Therapy 3:1, pages 19-29.
Crossref
Crossref
Mark R. Underwood, Lisa L. Ross, David M. Irlbeck, Peter Gerondelis, Elizabeth Rouse, Marty H. St. Clair, Lan Trinh, Neil Parkin & E. Randall Lanier. (2009) Sensitivity of Phenotypic Susceptibility Analyses for Nonthymidine Nucleoside Analogues Conferred by K65R or M184V in Mixtures with Wild-Type HIV-1. Journal of Infectious Diseases 199:1, pages 84-88.
Crossref
Crossref
M. Nijhuis, N.M. van Maarseveen & C.A.B. Boucher. 2009. Antiviral Strategies. Antiviral Strategies
299
320
.
Julian H Elliott, Lut Lynen, Alexandra Calmy, Andrea De Luca, Robert W Shafer, Maria Zolfo, Bonaventura Clotet, Sarah Huffam, Charles AB Boucher, David A Cooper & Jonathan M Schapiro. (2008) Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS 22:16, pages 2053-2067.
Crossref
Crossref
Odile Launay. (2008) Thérapeutiques antirétrovirales : principes du traitement de l’infection par le VIH. La Presse Médicale 37:6, pages 1022-1032.
Crossref
Crossref
Jean-Michel Molina. (2008) Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection. Drugs 68:5, pages 567-578.
Crossref
Crossref
Geoffrey J Yuen, Steve Weller & Gary E Pakes. (2008) A Review of the Pharmacokinetics of Abacavir. Clinical Pharmacokinetics 47:6, pages 351-371.
Crossref
Crossref
John K Ly, Nicolas A Margot, Holly L MacArthur, Magdeleine Hung, Michael D Miller & Kirsten L White. (2016) The Balance between NRTI Discrimination and Excision Drives the Susceptibility of HIV-1 RT Mutants K65R, M184V and K65R+M184V. Antiviral Chemistry and Chemotherapy 18:6, pages 307-316.
Crossref
Crossref
Andrea Antinori, Maria Paola Trotta, Patrizia Lorenzini, Carlo Torti, Nicola Gianotti, Franco Maggiolo, Francesca Ceccherini-Silberstein, Paola Nasta, Antonella Castagna, Andrea De Luca, Cristina Mussini, Massimo Andreoni & Carlo Federico Perno. (2007) Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation. Antiviral Therapy 12:8, pages 1175-1184.
Crossref
Crossref
Mark A WainbergJorge L Martinez-CajasBluma G Brenner. (2007) Strategies for the optimal sequencing of antiretroviral drugs toward overcoming and preventing drug resistance. Future HIV Therapy 1:3, pages 291-313.
Crossref
Crossref
R.M. Kagan, T.-S. Lee, L. Ross, R.M. LloydJr.Jr., M.A. Lewinski & S.J. Potts. (2007) Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. Antiviral Research 75:3, pages 210-218.
Crossref
Crossref
Martin Stürmer, Schlomo Staszewski & Hans Wilhelm Doerr. (2007) Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV. Antiviral Therapy 12:5, pages 695-704.
Crossref
Crossref
Jintanat Ananworanich. (2007) Reaching undetectable viral loads after initial HIV treatment. Future HIV Therapy 1:1, pages 81-89.
Crossref
Crossref
Bruce L. GilliamMohammad M. SajadiAnthony AmorosoCharles E. DavisFarley R. CleghornRobert R. Redfield. (2007) Tenofovir and Abacavir Combination Therapy: Lessons Learned from an Urban Clinic Population. AIDS Patient Care and STDs 21:4, pages 240-246.
Crossref
Crossref
Clare L TaylorEdmund GL Wilkins. (2007) Abacavir/lamivudine fixed-dose combination tablet for the treatment of HIV-1 infection. Future Virology 2:1, pages 11-21.
Crossref
Crossref
Anton Pozniak. (2006) Initiation of antiretroviral therapy. Current Opinion in Internal Medicine 5:6, pages 594-604.
Crossref
Crossref
Tomas Cihlar. (2006) Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond. Current Opinion in HIV and AIDS 1:5, pages 373-379.
Crossref
Crossref
Bernard Masquelier, Didier Neau, Sébastien Boucher, Valérie Lavignolle-Aurillac, Marie-Hélène Schrive, Patricia Recordon-Pinson, Jean-Marie Ragnaud & Hervé Fleury. (2006) Antiretroviral Efficacy and Virological Profile of a Zidovudine/Lamivudine/Tenofovir Disoproxil Fumarate Combination Therapy in Antiretroviral-Naive Patients. Antiviral Therapy 11:6, pages 827-830.
Crossref
Crossref